Amgen Arrives

Langreth, Robert
January 2006
Forbes Asia;1/9/2006, Vol. 2 Issue 1, p20
The article considers the efficacy of Amgen's drug panitumumab in reducing cancer progression. In November 2006, the Thousand Oaks, California company gained big win, when a final-stage test of advanced colon cancer patients found that the drug panitumumab reduced the rate of cancer progression by 46 percent. While hardly a cure, the drug may avoid the allergic reaction sometimes seen with Erbitux, made by Bristol-Myers Squibb and Imclone Systems.


Related Articles

  • Palifermin: In Myelotoxic Therapy-Induced Oral Mucositis. Siddiqui, M. Asif A.; Wellington, Keri // Drugs;2005, Vol. 65 Issue 15, p2139 

    â–´ Palifermin, a recombinant human keratinocyte growth factor (KGF), mimics the actions of endogenous KGF and has shown efficacy in the management of myelotoxic therapy-induced oral mucositis in cancer patients. â–´ In a randomised, double-blind trial in patients with haemtaological...

  • Why the AUC/MIC Ratio Should Not Be Used to Predict the Effects of b -Lactams. Mouton, Johan W. // Clinical Infectious Diseases;7/15/2002, Vol. 35 Issue 2, p209 

    Comments on an article about pharmacokinetic and pharmacodynamic (PK/PD) relationships. Application of PK/PD indices for predicting the effect of combination therapy; Influence of antibiotic area under the curve on the determination of drug effects; Analysis of drug effects.

  • Structure-based calculation of drug efficiency indices. Hetényi, Csaba; Maran, Uko; García-Sosa, Alfonso T.; Karelson, Mati // Bioinformatics;Oct2007, Vol. 23 Issue 20, p2678 

    Motivation: The efficiency indices (EI's) have been derived from the experimental binding affinities of drug candidates to macromolecules. These ‘two-in-one’ measures include information on both pharmacodynamics and pharmacokinetics of the candidate molecules. The time-consuming...

  • Commentary. Cheung, Amy // Evidence Based Mental Health;Feb2007, Vol. 10 Issue 1, p20 

    The author reviews the study regarding the safety of antidepressant treatment to children. He points out on a possible signal for increased risk in children and adolescents who are treated with antidepressants. He suggests that the findings should serve as a reminder to all clinicians, patients...

  • Potential of Amino Acid/Dipeptide Monoester Prodrugs of Floxuridine in Facilitating Enhanced Delivery of Active Drug to Interior Sites of Tumors: A Two-Tier Monolayer In Vitro Study. Tsume, Yasuhiro; Hilfinger, John; Amidon, Gordon // Pharmaceutical Research;Oct2011, Vol. 28 Issue 10, p2575 

    Purpose: To evaluate the advantages of amino acid/dipeptide monoester prodrugs for cancer treatments by assessing the uptake and cytotoxic effects of floxuridine prodrugs in a secondary cancer cell monolayer following permeation across a primary cancer cell monolayer. Methods: The first Capan-2...

  • Statins not linked with decreased risk for colorectal cancer. Shafer, Emily // Hem/Onc Today;7/10/2008, Vol. 9 Issue 12, p16 

    The article discusses research being done on the treatment of colorectal cancer. It references a study by D. J. Robertson et al which reveals that the use of statins does not have a relation to the development of colorectal cancer. It states that statin use was associated with a slight reduction...

  • ASCO ROUNDUP.  // BioWorld Today;6/4/2008, Vol. 19 Issue 108, p6 

    The article reports on the results of Celgene Corp.'s Phase III trial of Vidaza. The results indicated that the two-year survival rate for patients receiving Vidaza, a demethylating agent, was 50.8 percent, nearly doubled the 26.2 percent for conventional care regimens. The median overall...

  • Insulin intervention to preserve beta-cell function is effective, safe. Davis, Dawn Belt // Endocrine Today;8/10/2008, Vol. 6 Issue 14, p19 

    The article discusses research being done on insulin and beta-cell function. It references a study published in a 2008 issue of "Journal of Clinical Endocrinology & Metabolism." Researchers from the University of Yamanashi showed the safety and effectiveness of insulin intervention that...

  • The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. Josephson, Filip; Andersson, Maria; Flamholc, Leo; Gisslén, Magnus; Hagberg, Lars; Ormaasen, Vidar; Sönnerborg, Anders; Vesterbacka, Jan; Böttiger, Ylva // European Journal of Clinical Pharmacology;Apr2010, Vol. 66 Issue 4, p349 

    The relation between treatment outcome and trough plasma concentrations of efavirenz (EFV), atazanavir (ATV) and lopinavir (LPV) was studied in a pharmacokinetic/pharmacodynamic substudy of the NORTHIV trial—a randomised phase IV efficacy trial comparing antiretroviral-naïve human...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics